ASTH
Astrana Health, Inc. (ASTH) Management Analysis (2026)
Overall Score
Capital Allocation
Capital allocation appears balanced, with modest leverage and a current ratio of 1.23 supporting flexibility.
Dividend payout remains low at 4.8%, leaving room for reinvestment or debt reduction.
Free cash flow generation is solid, with FCF yield at 8.7% and FCF conversion near 90% of operating cash flow.
Leadership Execution
Execution is steady but not exceptional, with ROIC at 4.1% and ROE at 5.1% indicating only modest value creation.
Operating margins remain thin, with EBIT margin at 3.3% and net margin at 1.1%.
Asset efficiency is acceptable, as asset turnover is 1.68 and fixed asset turnover is high at 37.8.
Governance Alignment
No fresh news indicates governance or alignment changes this month.
Shareholder returns remain conservative, with a low dividend payout ratio and no dividend yield.
Balance sheet leverage is manageable, with debt-to-equity at 1.18 and net debt to EBITDA at 3.31.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Astrana Health, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

